AERA hikes Bangalore airport charges; IATA opposes the move

June 16, 2014

New Delhi, Jun 16: Airport tariff regulator AERA has fixed Rs 1,368 and Rs 342 per international and domestic passenger as user development fee (UDF) and other charges for Bangalore's Kempegowda airport but the airlines have opposed the ''over 100 per cent'' hike in tariff.Bangalore airport

In a latest order, the Airports Economic Regulatory Authority (AERA) also fixed charges for aircraft landing, parking, housing and other charges from July 1 till March 31 next year and higher tariff rates from April 1, 2015 till March end 2016.

While only UDF levels were lowered for 2015-16 to Rs1,226 for embarking international passengers and Rs 306 for domestic passengers, all the other tariffs were hiked for this period.

Terming the move as "a double whammy to Indian aviation", IATA's Regional Vice President (Asia Pacific) Conrad Clifford said in a statement that international airlines operating to Bangalore would now face "a steep increase in their operating costs with a 145 per cent increase in landing charges and a 105 per cent increase in parking charges".

The official of the global airlines body said it was also "disappointing" that AERA "deviated from the single till approach" in the case of Kempegowda International Airport which was "contrary to what AERA had previously opined that the single till approach was most appropriate for India".

"This deviation in policy can increase costs for airlines and passengers, thus negatively impacting traffic. This will hurt an already fragile Indian aviation industry," Clifford said, adding that funding airport development was "not a valid justification to deviate from the single till approach."

Under the 'single till' principle, airport activities, both aeronautical and commercial, are taken into consideration to determine the level of airport charges. By contrast, only aeronautical activities are taken into consideration under the dual till principle.

Maintaining that funding of the airport could be done through other means like equity, loans and bonds, Clifford said: "Instead, airport users are being penalised by being a convenient source of funding. They are unfairly made to pay for facilities that have yet to be built."

The International Air Transport Association (IATA) has been stressing that aviation should be treated as a strategic national asset that would pay dividends to the Indian economy.

Aviation supports 8.8 million Indian jobs and underpins 1.5 per cent of GDP, as per IATA figures.

"This could be a lot more. And the more globally connected that India is, the more opportunities will be created for jobs, trade and inward investment. AERA's decision is a step backwards for Indian aviation," the IATA officer said from Singapore.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 22,2020

New Delhi, Jan 22: Delhi Chief Minister Arvind Kejriwal has assets worth Rs 3.4 crore, an increase of Rs 1.3 crore from 2015, according to his election affidavit.

Kejriwal's total assets were worth Rs 2.1 crore in 2015.

The cash and fixed deposits of Kejriwal's wife Sunita Kejriwal increased from Rs 15 lakh in 2015 to Rs 57 lakh in 2020.

A party functionary said Rs 32 lakh worth cash and fixed deposits have been received by Sunita Kejriwal as voluntary retirement benefits while the rest are savings.

The cash and fixed deposits of the chief minister increased from Rs 2.26 lakh in 2015 to Rs 9.65 lakh in 2020.

There was no change in the value of immovable assets of his wife while Kejriwal's immovable assets' worth increased from Rs 92 lakh to Rs 177 lakh.

The party functionaries said increase in Kejriwal's immovable assets' worth is due to the increased valuation of the same asset as in 2015.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 25,2020

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 2,2020

Perambalur, Jan 2: Veteran Tamil writer Nellai Kannan was arrested in Perambalur for criticizing Prime Minister Narendra Modi and Home Minister Amit Shah during a protest against Citizenship (Amendment) Act.

The Tirunelveli Police had registered the FIR against the writer for the speech delivered at a meeting, which was called by the Social Democratic Party of India on December 29 last year.

The police have booked him on the basis of multiple complaints filed by BJP leaders.

Kannan has been booked under Sections 504, 505(1) and 505(2) of the Indian Penal Code.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.